Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Component 2: Core Viral Hepatitis Prevention Activities

Reporting Agency

Reporting jurisdiction	
Contact name (person completing form)	
Contact phone number (xxx-xxx-xxxx)	
Contact email address	
Additional contact name(s) (if applicable)	
Additional contact phone number(s) (xxx-xxx-xxxx)	
Additional contact email address(es)	
Date of report submission (MM/DD/YYYY)	
Reporting Period	Select one
(Complete this form with information from Reporting Period selected)	□ Year 1 (5/1/21-9/30/21)
	□ Year 2 (10/1/21-9/30/22)
	□ Year 3 (10/1/22-9/30/23)
	□ Year 4 (10/1/23-9/30/24)
	□ Year 5 (10/1/24-4/30/26)

2.1—Support viral hepatitis elimination planning and surveillance, and maximize access to testing, treatment, and prevention

Measures 2.1.1.a - 2.1.1.b

- Establishment and maintenance of a viral hepatitis elimination technical advisory committee (or coalition) with membership to support jurisdictional viral hepatitis elimination planning
- Conduct at least two meetings per year of the viral hepatitis elimination technical advisory committee (or coalition)

Have you established a viral hepatitis	Select one	
elimination technical advisory committee	□ Completed	□ Not started
(or coalition) to support viral hepatitis elimination planning?	□ In progress	
Identify the stakeholder groups that are	□ Public health	□ Laboratories
(or will be) represented on this committee (or coalition).	□ Corrections	□ Community-based organizations
(Select all that apply)	□ Criminal justice, law enforcement	Local harm reduction coalition members
	□ Medicaid	□ Non-profit/advocacy groups
	☐ Injury prevention services	☐ People with viral hepatitis lived
	☐ Substance use and mental	experience
	health services	□ Other, specify:
	☐ Healthcare providers	>>
	☐ HIV care providers	□ N/A (committee not established)
	□ Hospitals	

During this reporting period, when did the >			>		
committee (or coalition) meet? (MM/DD/YYYY)	>		>		
	□ No meetings h	eld during	g reporting period		
	□ N/A (committee	not establis	shed)		
If the committee (or coalition) met during t	⊥ his reporting period	. please	Select one		
submit a copy of meeting agenda(s) with		′ •	☐ Submitted ☐ Not submitted		
			□ N/A (committee not established)		
			1477 (committee not established)		
Measure 2.1.1.c • Development and maintenance of a viral hepatit	is elimination plan with	support fro	om the technical advisory committee (or coalition		
Have you developed a viral hepatitis elimin	ation plan?	Select	one		
		□ Comp	oleted Not started		
		□ In pro	progress		
Does it contain plans for elimination of hep	atitis C and/or	□ Hepat	titis C		
hepatitis B?		□ Hepatitis B			
(select all that apply) If the viral hepatitis elimination plan is com	pleted, please	Select	one		
submit a sony with the ADD		□ Subm			
			plan not started)		
			pian not startedy		
 Measures 2.1.2.c, 2.1.4.a The jurisdictional viral hepatitis elimination plan The jurisdictional viral hepatitis elimination plan 					
Does your viral hepatitis elimination plan a	Select one				
for increasing HCV RNA reflex testing?			Yes		
			no		
Does your viral hepatitis elimination plan a	ddress provider trai	_	Select one		
in prescribing hepatitis C treatment?			Yes		
			No		
Does your viral hepatitis elimination plan a	ddress provider trai		Select one		
in prescribing hepatitis B treatment?		8	Sciect one		
			J Ves □ N/Λ (plan not started)		
			Yes		
			Yes		
Measures 2.1.2.a - 2.1.2.b CLIA-certified laboratories that conduct testing for the proportion conducting HCV RNA reflex testing for the		ti-HCV resul	No No llts identified in the jurisdiction		
 CLIA-certified laboratories that conduct testing f The proportion conducting HCV RNA reflex testion 	ng was assessed; feedb	ti-HCV resulack with rec	No alts identified in the jurisdiction commendations conducted		
CLIA-certified laboratories that conduct testing f	ng was assessed; feedb	ti-HCV resulack with rec	Ilts identified in the jurisdiction commendations conducted Select one		
 CLIA-certified laboratories that conduct testing f The proportion conducting HCV RNA reflex testing Have you worked with your surveillance a 	ng was assessed; feedb and/or epidemiolo A-certified laborato	ati-HCV resulack with rec	No alts identified in the jurisdiction commendations conducted		

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Of the CLIA-certified laboratories you have identified that report	Select one	
hepatitis C antibody testing results, have you selected the subset	□ Yes	□ In progress
that reports at least 80% of the hepatitis C antibody testing results in your jurisdiction?	□ No	□ N/A (labs not identified)
Of this subset, have you performed a needs assessment to identify	Select one	
key barriers and challenges to increasing HCV RNA reflex testing?	□ Yes	□ In progress
	□ No	$\ \square$ N/A (labs not identified)
What proportion of the subset is conducting HCV RNA reflex	Select one	
testing?	%:	□ In progress
		$\ \square$ N/A (labs not identified)
Have you provided recommendations to increase HCV RNA reflex	Select one	
testing?	□ Yes	□ In progress
	□ No	□ N/A (labs not assessed)

Measures 2.1.3.a - 2.1.3.b

- The top 5 highest volume health systems in the jurisdiction identified
- The proportion of health systems promoting routine HCV and HBV testing assessed; feedback with recommendations was conducted

What are the top 5 highest volume	1.		
health systems in your jurisdiction? 2.			
	3.		
	4.		
	5.		
	□ In progress		
	□ Not started		
Have you assessed how many of these health systems are		Select one	
promoting routine HCV testing?		□ Completed	□ Not started
		□ In progress	□ N/A (health systems not assessed)
If so, what percent of health systems are promoting routine HCV		%:	☐ In progress
testing?			\square N/A (health systems not assessed)
Have you assessed how many of these health systems are promoting routine HBV testing?		Select one	
		□ Completed	□ Not started
		□ In progress	□ N/A (health systems not assessed)
If so, what percent of health systems	are promoting routine HBV	%:	□ In progress
testing?			\square N/A (health systems not assessed)

or HBV testing?		Select one		
		□ Yes, to all 5	☐ Yes, to some but not all	
		□ No, have not provided feedback to any of them	□ N/A (health systems not assessed)	
Please use this space to provide information about challenges and successes experienced when implementing Strategy 2.1 activities. Include additional contextual information that would help us interpret your annual performance data.				

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

	Was Section 2.2 funded?	Select one	□ No NOTE: Stop here if not funded	□ Yes
--	-------------------------	------------	------------------------------------	-------

2.2—Increase access to hepatitis C and/or hepatitis B testing and referral to care in high-impact settings

Measures 2.2.2.a - 2.2.2.b

- Jurisdiction established relationship with partners in high-impact settings to identify high priority facilities for expansion of testing
 for HCV and/or HBV in high-impact settings, by setting type (syringe services programs, substance use disorder treatment programs,
 correctional facilities, emergency departments, hospital-based programs, sexually transmitted disease clinics, homeless services,
 health centers, other)
- Number of clients seen, by setting

During the reporting period, were component 2 activities conducted at one or more syringe services programs (SSPs)?
□ Yes
□ No
During the reporting period, were component 2 activities conducted at one or more substance use disorder (SUD) treatment programs (non-hospital based)?
□ Yes
□ No
During the reporting period, were component 2 activities conducted at one or more <u>hospital-based</u> substance use disorder (SUD) treatment programs?
□ Yes
□ No
During the reporting period, were component 2 activities conducted at one or more hospital-based programs (<u>excluding</u> SUD treatment programs which are included separately above)?
□ Yes
□ No
During the reporting period, were component 2 activities conducted at one or more health centers (non-hospital based)?
□ Yes
□ No
During the reporting period, were component 2 activities conducted at one or more sexually transmitted infections (STI) clinics?
□ Yes
□ No
During the reporting period, were component 2 activities conducted at one or more mobile

clinics?
□ Yes
□ No
During the reporting period, were component 2 activities conducted at one or more emergency departments?
□ Yes
□ No
During the reporting period were component 2 activities conducted at one or more correctional facilities?
□ Yes
□ No
During the reporting period were component 2 activities conducted at one or more homeless services?
□ Yes
□ No
During the reporting period, were component 2 activities conducted at another type of setting?
□ Yes, specify:
□ No
Note: If more than one other type of setting, list the first other type here and describe the additional other type(s) individually in the following questions.
During the reporting period, were component 2 activities conducted at a second other type of setting?
□ Yes, specify:
□ No
Note: If more than two other types of settings, list the second other type here and describe the additional other type(s) individually in the following questions.
During the reporting period, were component 2 activities conducted at a third other type of setting?
□ Yes, specify:
□ No

Setting type	Was relationship established to expand HCV testing?	Was relationship established to expand HBV testing?	Number of clients seen at this setting during reporting period
	Select one	Select one	>
	□ Yes	□ Yes	□ Unknown

SSPs	□ No	□ No	
questions will be skipped if not applicable	□ In progress	□ In progress	
	Select one	Select one	>
	□ Yes	□ Yes	□ Unknown
SUD treatment programs, <u>non-</u>	□ No	□ No	
hospital based questions will be skipped if not applicable	☐ In progress	□ In progress	
4	Select one	Select one	>
CLID to a to a cut our annual	□ Yes	□ Yes	□ Unknown
SUD treatment programs, hospital-based	□ No	□ No	
questions will be skipped if not applicable	□ In progress	□ In progress	
Hospital-based programs	Select one	Select one	>
(<u>excluding</u> SUD treatment	□ Yes	□ Yes	□ Unknown
programs which are included separately above)	□ No	□ No	
questions will be skipped if not applicable	□ In progress	□ In progress	
Health centers (non-hospital	Select one	Select one	>
based)	□ Yes	□ Yes	□ Unknown
questions will be skipped if not applicable	□ No	□ No	
	□ In progress	☐ In progress	
	Select one	Select one	>
CTI elimina	□ Yes	□ Yes	□ Unknown
STI clinics	□ No	□ No	
questions will be skipped if not applicable	□ In progress	□ In progress	
	Select one	Select one	>
Mobile clinics	□ Yes	□ Yes	□ Unknown
questions will be skipped if not applicable	□ No	□ No	
	□ In progress	□ In progress	
	Select one	Select one	>
	□ Yes	□ Yes	□ Unknown
Emergency departments	□ No	□ No	
questions will be skipped if not applicable	☐ In progress	□ In progress	
Correctional facilities	Select one	Select one	>
questions will be skipped if not applicable	□ Yes	□ Yes	□ Unknown
	□ No	□ No	
	☐ In progress	☐ In progress	
Homeless services	Select one	Select one	>
questions will be skipped if not applicable	□ Yes	□ Yes	□ Unknown

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

	□ No	□ No	
	□ In progress	□ In progress	
	Select one	Select one	>
Other type of setting described	□ Yes	□ Yes	□ Unknown
above, first	□ No	□ No	
questions will be skipped if not applicable	□ In progress	□ In progress	
	Select one	Select one	>
Other type of setting described	□ Yes	□ Yes	□ Unknown
above, second	□ No	□ No	
questions will be skipped if not applicable	□ In progress	□ In progress	
Other type of setting described	Select one	Select one	>
above, third	□ Yes	□ Yes	□ Unknown
questions will be skipped if not applicable	□ No	□ No	
	□ In progress	□ In progress	

Measures 2.2.2.c - 2.2.2.f, 2.2.3.a

- Number of clients screened for hepatitis C (anti-HCV), by setting
- Number of clients positive for anti-HCV, by setting
- Number of clients tested for HCV RNA, by setting
- Number of clients positive for HCV RNA, by setting
- Number of clients positive for HCV RNA linked to treatment, by setting

		During this reporting period, number of:					
Setting type	Clients screened for hepatitis C (anti-HCV)	Clients positive for anti-HCV	Clients tested for HCV RNA	Clients positive for HCV RNA	Clients positive for HCV RNA linked to hepatitis C treatment		
SSPs	>	>	>	>	>		
questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	□ Unknown	□ Unknown		
SUD treatment programs,	>	>	>	>	>		
non-hospital based questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	□ Unknown	□ Unknown		
SUD treatment programs,	>	>	>	>	>		
hospital based questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	□ Unknown	□ Unknown		
Hospital-based programs	>	>	>	>	>		

(excluding SUD treatment programs which are included separately above) questions will be skipped if not	□ Unknown				
applicable					
Health centers (non - hospital based)	>	>	>	>	>
questions will be skipped if not	□ Unknown				
applicable					
STI clinics	>	>	>	>	>
questions will be skipped if not applicable	□ Unknown				
Mobile clinics	>	>	>	>	>
questions will be skipped if not applicable	□ Unknown				
Emergency departments	>	>	>	>	>
questions will be skipped if not applicable	□ Unknown				
Correctional facilities	>	>	>	>	>
questions will be skipped if not applicable	□ Unknown				
Homeless services	>	>	>	>	>
questions will be skipped if not applicable	□ Unknown				
Other type of setting	>	>	>	>	>
described above, first	□ Unknown				
questions will be skipped if not applicable					
Other type of setting	>	>	>	>	>
described above, second	□ Unknown				
questions will be skipped if not applicable					
Other type of setting	>	>	>	>	>
described above, third	□ Unknown				
questions will be skipped if not applicable					

- Number of clients screened for hepatitis B, by setting
- Number of clients positive for HBsAg, by setting
- Number of clients positive for HBsAg linked to care, by setting

	During this	reporting period	, number of:	
Setting type	Clients screened for hepatitis B	Clients positive for HBsAg	Clients positive for HBsAg linked to hepatitis B care	
SSPs	>	>	>	
questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	
SUD treatment programs,	>	>	>	
<u>non</u> -hospital based	□ Unknown	□ Unknown	□ Unknown	
questions will be skipped if not applicable				
SUD treatment programs, hospital-based	>	>	>	
questions will be skipped if not	□ Unknown	□ Unknown	□ Unknown	
applicable				
Hospital-based programs	>	>	>	
(<u>excluding</u> SUD treatment	□ Unknown	□ Unknown	□ Unknown	
programs which are included separately				
above)				
questions will be skipped if not applicable				
Health centers (non-	>	>	>	
hospital based)	□ Unknown	□ Unknown	□ Unknown	
questions will be skipped if not applicable				
STI clinics	>	>	>	
questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	
Mobile clinics	>	>	>	
questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	
Emergency departments	>	>	>	
questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	
Correctional facilities	>	>	>	
questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	

Homeless services	>	>	>
questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown
Other type of setting	>	>	>
described above, first	□ Unknown	□ Unknown	□ Unknown
questions will be skipped if not applicable			
Other type of setting	>	>	>
described above, second	□ Unknown	□ Unknown	□ Unknown
questions will be skipped if not applicable			
Other type of setting	>	>	>
described above, third	□ Unknown	□ Unknown	□ Unknown
questions will be skipped if not applicable			

Please use this space	
to provide information about challenges and	
successes experienced when implementing	
Strategy 2.2 activities. Include additional	
contextual information that would help us	
interpret your annual performance data.	

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

|--|

2.3—Improve access to services preventing viral hepatitis and other bloodborne infections among people who inject drugs (PWID)

Measures 2.3.3.a - 2.3.3.d

- Number of hepatitis A vaccination doses administered to clients in the high-impact settings, by setting
- Number of clients in the high-impact settings who completed hepatitis A vaccination series, by setting
- Number of hepatitis B vaccination doses administered to clients in the high-impact settings, by setting
- Number of clients in the high-impact settings who completed hepatitis B vaccination series, by setting

	During this reporting period, number of:				
Setting type	Hepatitis A vaccination doses administered	Clients who completed hepatitis A vaccination series	Hepatitis B vaccination doses administered	Clients who completed hepatitis B vaccination series	
SSPs	>	>	>	>	
questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	□ Unknown	
SUD treatment	>	>	>	>	
programs, <u>non</u> - hospital based	□ Unknown	□ Unknown	□ Unknown	□ Unknown	
questions will be skipped if not applicable					
SUD treatment	>	>	>	>	
programs, <u>hospital</u> - based	□ Unknown	□ Unknown	□ Unknown	□ Unknown	
questions will be skipped if not applicable					
Hospital-based programs (excluding SUD treatment programs which are included separately above) questions will be skipped if not applicable	> □ Unknown	> □ Unknown	> □ Unknown	> □ Unknown	
Health centers (non-	>	>	>	>	
hospital based) questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	□ Unknown	
STI clinics	>	>	>	>	

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	□ Unknown
Mobile clinics	>	>	>	>
questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	□ Unknown
Emergency	>	>	>	>
departments	□ Unknown	□ Unknown	□ Unknown	□ Unknown
questions will be skipped if not applicable				
Correctional facilities	>	>	>	>
questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	□ Unknown
Homeless services	>	>	>	>
questions will be skipped if not applicable	□ Unknown	□ Unknown	□ Unknown	□ Unknown
Other type of setting	>	>	>	>
described above, first	□ Unknown	□ Unknown	□ Unknown	□ Unknown
questions will be skipped if not applicable				
Other type of setting	>	>	>	>
described above,	□ Unknown	□ Unknown	□ Unknown	□ Unknown
second				
questions will be skipped if not applicable				
Other type of setting	>	>	>	>
described above, third	□ Unknown	□ Unknown	□ Unknown	□ Unknown
questions will be skipped if		I		I

Measures 2.3.1.a - 2.3.1.d, 2.3.2.a

- Number of syringe services programs (SSPs) in the jurisdiction
- Number of visits in the jurisdiction, by SSP
- Number of unduplicated SSP clients in the jurisdiction, by SSP
- Mean (median) syringe coverage rates, by SSP
- Number of clients linked to substance use disorder treatment by SSPs in the jurisdiction, by SSP

	During th			
Syringe services programs (SSPs) in jurisdiction	Total client visits	Unduplicated SSP clients	Clients linked to substance use disorder treatment	Mean syringe coverage rates during this reporting period

SSP 1 Name: >	> □ Unknown	> Unknown	> □ Unknown	Mean=
SSP 2 Name:	> Unknown	>	> Unknown	Mean=
SSP 3 Name:	> Unknown	> Unknown	> Unknown	Mean=
SSP 4 Name: >	> Unknown	> Unknown	> Unknown	Mean=
SSP 5 Name:	> Unknown	> Unknown	> Unknown	Mean=
SSP 6 Name: >	> Unknown	> Unknown	> □ Unknown	Mean=
SSP 7 Name:	> Unknown	> Unknown	> □ Unknown	Mean=
SSP 8 Name: >	> Unknown	> Unknown	> Unknown	Mean=
SSP 9 Name: >	> Unknown	> Unknown	> □ Unknown	Mean=
SSP 10 Name:	> Unknown	> Unknown	> Unknown	Mean=
SSP 11 Name:	> Unknown	> Unknown	> Unknown	Mean=
SSP 12 Name: >	> Unknown	> Unknown	> □ Unknown	Mean=

SSP 13	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
>				
CCD 4.4				Mann
SSP 14 Name:	>	>	>	Mean=
> >	□ Unknown	□ Unknown	□ Unknown	
SSP 15	>	>	>	Mean=
Name:		□ Unknown	□ Unknown	Through
>	□ Unknown	Onknown	L OHKHOWH	
SSP 16	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
>				
SSP 17	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
SSP 18	>	>	>	Mean=
Name:				IVICALI-
>	□ Unknown	□ Unknown	□ Unknown	
SSP 19	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
>	- Chikhowh	- Chikhowh	- CIRCIOWII	
SSP 20	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
SSP 21	>	>	>	Mean=
Name:				Medit
>	□ Unknown	□ Unknown	□ Unknown	
SSP 22	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
>				
CCD 22		>	>	Moone
SSP 23 Name:	>			Mean=
> >	□ Unknown	□ Unknown	□ Unknown	
SSP 24	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
>	- CHRIOWII	OHKHOWH	OHKHOWH	

SSP 25 Name: >	> □ Unknown	> Unknown	> □ Unknown	Mean=
SSP 26 Name:	>	>	> Unknown	Mean=
SSP 27 Name:	> Unknown	> Unknown	> Unknown	Mean=
SSP 28 Name: >	> Unknown	> Unknown	> Unknown	Mean=
SSP 29 Name: >	> Unknown	> Unknown	> Unknown	Mean=
SSP 30 Name: >	> Unknown	> Unknown	> □ Unknown	Mean=
SSP 31 Name:	> Unknown	> Unknown	> □ Unknown	Mean=
SSP 32 Name:	> Unknown	> Unknown	> Unknown	Mean=
SSP 33 Name:	> Unknown	> Unknown	> □ Unknown	Mean=
SSP 34 Name:	> Unknown	> Unknown	> Unknown	Mean=
SSP 35 Name:	> Unknown	> Unknown	> Unknown	Mean=
SSP 36 Name:	> Unknown	> Unknown	> Unknown	Mean=

SSP 37	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
>				
SSP 38	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
>				
SSP 39	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
SSP 40	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
CCD 44				N.4
SSP 41	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
CCD 40	_		>	N4
SSP 42 Name:	>	>		Mean=
> >	□ Unknown	□ Unknown	□ Unknown	
SSP 43	>	>	>	Mean=
Name:				IVICALI-
>	□ Unknown	□ Unknown	□ Unknown	
SSP 44	>	>	>	Mean=
Name:	= Unionavio	= Union accom		
>	□ Unknown	□ Unknown	□ Unknown	
SSP 45	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
>	- OTIKITOWIT	- Chikhowh	- Chikhowh	
SSP 46	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
>				
SSP 47	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
>				
SSP 48	>	>	>	Mean=
Name:	> Unknown	> Unknown	> Unknown	Mean=
				Mean=

SSP 49	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
>				
SSP 50	>	>	>	Mean=
Name:	□ Unknown	□ Unknown	□ Unknown	
Please use this				
space				
to provide				
information				
about				
challenges and				
successes				
experienced				
when				
implementing				
Strategy 2.3				
activities.				
Include				
additional				
contextual				
information				
that would				
help us				
interpret your				
annual				
performance				
data.				